Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

diluted net loss per common share

include deemed dividends, preferred stock accretion, and changes in

the fair value of warrant liability.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and webcast today, Thursday, August 7, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-340-7913 (U.S./Canada) or 719-325-4847 (international).

The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.

A telephonic replay will also be available beginning today at 8 P.M. EDT for seven days through Thursday, August 14. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8324472.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ewswire/ -- The FDA granted traditional approval f...leoside reverse transcriptase inhibitor (NNRTI). I...for use in treatment-experienced adults who are ex...sistant to an NNRTI and other antiretroviral (ARV)...week data from two Phase 3 studies known as DUET-1...
(Date:11/25/2009)...5 AMPAC Fine Chemicals LLC (AFC), ...aq: APFC ) announced today that it received the E...rd at the Annual Statewide Environmental Summit, s...ology Association (CMTA), the Industrial Environme...ouncil of California (CICC) held in San Diego. Th...
(Date:11/25/2009)...swire/ -- Reportlinker.com announces that a new ma...: ,, United States Dental Devices Market Analy...tlinker.com/p0158733/United-States-Dental-Devices-...United States Dental Devices Market Analysis and F... is an essential source for in-depth information a...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD Related Sleep Disturbances 47601 1AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD Related Sleep Disturbances 47601 2AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD Related Sleep Disturbances 47601 3AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD Related Sleep Disturbances 47601 4AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD Related Sleep Disturbances 47601 5Cordex Receives Special Protocol Assessment Approval from FDA for ATPace 28TM 29 47599 1Cordex Receives Special Protocol Assessment Approval from FDA for ATPace 28TM 29 47599 2Cordex Receives Special Protocol Assessment Approval from FDA for ATPace 28TM 29 47599 3Cordex Receives Special Protocol Assessment Approval from FDA for ATPace 28TM 29 47599 4Orexigen 28R 29 Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings 12414 1Orexigen 28R 29 Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings 12414 2
... Javelin,Pharmaceuticals, Inc. (AMEX: JAV), a lead...today announced that its Phase 2,multi-dose study ...ficial journal of The American Academy of Pain Med...and Safety of,Morphine-Chitosan Nasal Solution in ...thopedic Surgery", was recently made,available onl...
... Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) a bio...eloping, and commercializing small,molecule drugs ...d,encouraging results from the analysis of overall...double-blind, randomized, controlled,multi-center...r its,lead compound, STA-4783., The analysis of ov...
Other Medicine Technology:Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 2Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 3Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 2Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 3Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 4Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 5Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 6Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 7
(Date:11/27/2009)...NA, BC, Nov. 27 /PRNewswire/ - Uploadable USB pedo...e time in wellness. A combination of advanced acce...are solving a long term concern over the accuracy ...tely gauge and reward improved participation in a ...one of the first wellness suppliers to integrate t...
(Date:11/27/2009)...AS, Nov. 27 Considered ... only 25 years ago, solid organ transplantation is...the extraordinary men and women who gathered at th...rs came together from medical centers around the w...egional Transplant Institute (BRTI), one of the pi...
(Date:11/27/2009)...ESTER, N.Y., Nov. 27 Pr...provider and fortunately every year, new vaccines ...ut do all vaccines boost immunity for the same per...ster shots, needed to keep immunity strong? ,... of the American Academy of Pediatrics, Michael Pi...
(Date:11/27/2009)...TZ SHAMIR, Israel, Nov. 27 /PRNewswire-FirstCall/ ... "Shamir" ), a leading provider of innovative prod... announced today that its board of directors had d...ount of US$ 10 million (approximately NIS 37.62 mi...e rate of exchange), or approximately US$ 0.609 (a...
(Date:11/27/2009)...ing plus low-emission vehicles may reduce future d...Y, Nov. 27 (HealthDay News) -- Encouraging city dw...ould offer much greater public health benefits tha...searchers have found. , The study compared the ...ban land transport scenarios for London, England, ...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2
...to a US study insomnia or loss of sleep affects fi...oute and navigation and there is difficulty findin...n rats. When sleep was tampered with rats' spat...roups of rats were studied, putting one in a water...
...s at Georgetown University’s Lombardi Comprehensiv...cancer properties of Vitamin D from its other func...epted that Vitamin D helps protect against colorec...e to separate the two functions at the molecular l...
... Campbell in Portland Square are quitting the NHS ...sign up the new national health contracts by April...pted out. Previously dentists had to give their pa...ria Primary Care Trusts (PCTs) cannot yet say how ...
...cial has said that the AIDS/HIV population has bee... 43 percent of its population being infected, incl...-29. // Swaziland and Lesotho, with a preva...t, Stephen Lewis, the UN special envoy for HIV/AID...
...rl is recovering well, after a cancer unit adminis...a Norris, is trying to re-build her life, and is c... She has re-joined school and will be celebrating ...atson Oncology Centre in Glasgow. She was being tr...
...s conducted a new study and found that smoking mak... consumption. // Dieter Meyerhoff, professor o...rancisco said that smoking interferes with the bra...lcoholics who smoked showed much less improvement ...
Other Medicine News:Health News:Swaziland And Lesotho Sees Sharp Increase In AIDS/HIV Population 2
Excell 16 Hematology System
...™ is a therapeutic, expandable turning surfa...CATIONS , Prevention and treatment of pressure ul...rge patients using a statuc mattress that would be...se body weight and size pose a significant risk or...
...e; 300 is a healthcare bed system which helps prov... care setting, ,INDICATIONS: ,Patients weighing u...e frame accommodating one or two individuals, depe... ,Total weight in excess of 600 lbs. (including ac...
... providing a flexible environment for patient care...r comfort, support, treatment and prevention., ,I.... ,Large patients at risk for pressure ulcers ,Any...benefit from a pressure reduction surface ,Patient...
Medicine Products: